Poland

 

HBI 2023: Managing your costs in challenging times

Rising costs from inflation, wages, and energy are indiscriminately hitting the health care sector and despite government support packages being pledged, the road ahead looks arduous. So how do providers control costs, and what are the strategies to keep costs at bay?
July 15, 2023

HBI 2023: The outpatient differential

For years there has been a trend towards using outpatient services wherever possible - to improve patient outcomes, to better use an increasingly scarce workforce, and to increase cost efficiency. On the “Outpatient differential” panel at HBI 2023, how this push looks across the world was a key topic for discussion.
July 12, 2023

Is Orpea set to sell up in Belgium?

Multiple sources tell HBI that French nursing home operator Orpea is looking to sell up in Belgium, as it looks to sell off a chunk of its 1.2bn real estate portfolio. HBI also hears more speculation on the ongoing country-by-country review.
June 30, 2023

Penta’s fight with Slovak government continues

The Slovak government is refusing to allow the state-owned National Health Insurance Fund (NHIF) to pay for any treatments at Bory Hospital - the new €250m, 400-bed facility that Penta Hospitals International (owned by Penta Investments) has recently opened in Bratislava. The refusal marks another round in the battle between Penta and the Slovak state.
June 30, 2023

Orpea restructuring: What will it look to sell?

It has been almost six months since under-fire French nursing home giant Orpea announced plans to get its core business back on track, restructure its debt, and sell around €1.2bn worth of real estate over the next three years. As discussions separating the wheat from the chaff go on behind closed doors, HBI asks three experts where, and what it might sell, and reviews what other French operators like Korian are doing to repair reputation.
May 5, 2023

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 
April 19, 2023

Diaverum deal: An analysis

Last week the news broke that Abu Dhabi sovereign wealth fund Mubadala Investment Co might be set to buy Swedish multinational dialysis firm Diaverum for a reported $2.5bn. HBI speaks to an operator source who thinks this would be a good price for the seller - and hears why some investors are switched off by dialysis.
April 6, 2023

Cinven looks to take Synlab private as Covid boost falters

Frankfurt-listed Synlab could be about to be taken private following a non-binding full takeover offer earlier this week. With its full year results released yesterday and facing questions about its plans, HBI asks market experts what they think of the move.
March 17, 2023
Newer posts
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us